Mobile

An investigational study to assess the safety and efficacy of a new investigational drug in subjects with compensated liver cirrhosis secondary to non-alcoholic steatohepatitis (NASH)

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-002489-11

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate whether simtuzumab (formerly referred to as GS-6624) can reduce portal venous pressure and incidence of clinical events in subjects with cirrhosis due to NASH.

Critère d'inclusion

  • Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Liens